STELLAR-305：zan zalintinib联合帕博利珠单抗对比单独使用帕博利珠单抗治疗头颈部鳞状细胞癌患者的II/III期研究。
STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC.
作者信息
Saba Nabil F, Harrington Kevin, Licitra Lisa, Machiels Jean-Pascal, He Cixin, Jew Taylor, Andrianov Vasily, Haddad Robert
机构信息
Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA.
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
出版信息
Future Oncol. 2025 May;21(11):1349-1356. doi: 10.1080/14796694.2025.2485015. Epub 2025 Apr 18.
Abstract
TWEETABLE ABSTRACT
STELLAR-305: design of an ongoing phase III #clinicaltrial, assessing the multi-targeted tyrosine kinase inhibitor, zanzalintinib, in combination with pembrolizumab in previously untreated recurrent/metastatic #HNSCC.
CLINICAL TRIAL REGISTRATION
NCT06082167 (ClinicalTrials.gov).
摘要
可发布推文的摘要
STELLAR - 305：一项正在进行的III期#临床试验设计，评估多靶点酪氨酸激酶抑制剂赞扎替尼与帕博利珠单抗联合用于既往未治疗的复发/转移性#头颈部鳞状细胞癌。
临床试验注册
NCT06082167（ClinicalTrials.gov）。
相似文献
1
STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC.STELLAR-305：zan zalintinib联合帕博利珠单抗对比单独使用帕博利珠单抗治疗头颈部鳞状细胞癌患者的II/III期研究。
Future Oncol. 2025 May;21(11):1349-1356. doi: 10.1080/14796694.2025.2485015. Epub 2025 Apr 18.
2
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC.LiGeR-HN关于培托西单抗+帕博利珠单抗和培托西单抗单药治疗复发性或转移性头颈部鳞状细胞癌的III期试验。
Future Oncol. 2025 Jul;21(16):2007-2016. doi: 10.1080/14796694.2025.2511470. Epub 2025 Jun 13.
3
STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer.STELLAR-303：曾接受治疗的转移性结直肠癌中 zanzalintinib+atezolizumab 的随机 III 期研究。
Future Oncol. 2024;20(24):1733-1743. doi: 10.1080/14796694.2024.2352276. Epub 2024 Jul 23.
4
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
5
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
6
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
8
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.仑伐替尼联合帕博利珠单抗治疗未经治疗的晚期肾细胞癌：系统评价和成本效果分析。
Health Technol Assess. 2024 Aug;28(49):1-190. doi: 10.3310/TRRM4238.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗：一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
10
Safety and efficacy of neoadjuvant therapy with tislelizumab plus chemotherapy for locally advanced head and neck squamous cell carcinoma: a single-arm, retrospective study.替雷利珠单抗联合化疗用于局部晚期头颈部鳞状细胞癌新辅助治疗的安全性和有效性：一项单臂回顾性研究。
Cancer Immunol Immunother. 2025 Feb 11;74(3):108. doi: 10.1007/s00262-025-03953-0.
本文引用的文献
1
Advances in understanding cisplatin-induced toxicity: Molecular mechanisms and protective strategies.顺铂诱导毒性的研究进展：分子机制与保护策略。
Eur J Pharm Sci. 2024 Dec 1;203:106939. doi: 10.1016/j.ejps.2024.106939. Epub 2024 Oct 17.
2
Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis.帕博利珠单抗联合卡博替尼治疗复发性和/或转移性头颈部鳞状细胞癌：基于生物标志物分析的长期生存更新。
Clin Cancer Res. 2024 Oct 15;30(20):4601-4608. doi: 10.1158/1078-0432.CCR-24-1202.
3
Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC).铂类/紫杉类/帕博利珠单抗对比铂类/5-FU/帕博利珠单抗在复发性/转移性头颈部鳞状细胞癌（r/m HNSCC）中的应用。
Oral Oncol. 2024 Nov;158:106997. doi: 10.1016/j.oraloncology.2024.106997. Epub 2024 Aug 17.
4
STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer.STELLAR-303：曾接受治疗的转移性结直肠癌中 zanzalintinib+atezolizumab 的随机 III 期研究。
Future Oncol. 2024;20(24):1733-1743. doi: 10.1080/14796694.2024.2352276. Epub 2024 Jul 23.
5
MET Oncogene Targeting for Cancer Immunotherapy.MET 癌基因靶向治疗用于癌症免疫治疗。
Int J Mol Sci. 2024 Jun 1;25(11):6109. doi: 10.3390/ijms25116109.
6
The predictive role of PD-L1 in head and neck cancer: A systematic review and meta-analysis.PD-L1 在头颈部癌症中的预测作用：系统评价和荟萃分析。
Oral Oncol. 2024 Jun;153:106799. doi: 10.1016/j.oraloncology.2024.106799. Epub 2024 May 9.
7
Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy.在复发性或转移性头颈部鳞状细胞癌中开拓新天地：超越 PD-L1 免疫疗法的新型疗法。
Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e433330. doi: 10.1200/EDBK_433330.
8
Therapeutic targeting of the functionally elusive TAM receptor family.靶向功能隐匿的 TAM 受体家族的治疗方法。
Nat Rev Drug Discov. 2024 Mar;23(3):201-217. doi: 10.1038/s41573-023-00846-8. Epub 2023 Dec 13.
9
TAM family kinases as therapeutic targets at the interface of cancer and immunity.酪氨酸激酶家族作为癌症与免疫交叉领域的治疗靶点。
Nat Rev Clin Oncol. 2023 Nov;20(11):755-779. doi: 10.1038/s41571-023-00813-7. Epub 2023 Sep 4.
10
Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.派姆单抗联合卡博替尼治疗复发性转移性头颈部鳞状细胞癌：一项 2 期临床试验。
Nat Med. 2023 Apr;29(4):880-887. doi: 10.1038/s41591-023-02275-x. Epub 2023 Apr 3.
Zotero 插件